NRG Oncology/RTOG 0926: Phase II Protocol for Patients With Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent With Radiosensitizing Chemotherapy Following a Thorough Transurethral Surgical Re-Staging

Trimodality bladder preservation therapy is an effective treatment option for patients with recurrent high grade, non-muscle invasive urothelial cancer of the bladder. At three years, nearly 90% of patients remained free of cystectomy, although the overall survival was only 69% likely reflecting the age and comorbidities of this population. Bladder preservation is an effective bladder cancer treatment strategy yet remains underutilized.